MECOM and myeloid leukemia: In the CGD trial, the insertional activation of the MDS1-EVI1 genes (EVI1 is a transcription factor involved in the development of some myeloid leukemias [14]) may have contributed to clinical benefit but also led to a clonal myeloproliferation resembling a pre-leukemic state [12].